The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
PBX shortlisted
https://www.bioprocessonline.com/doc/cphi-barcelona-announces-pharma-award-finalists-0001
unfortunately we didn't win
https://europe.cphi.com/europe/en/awards/awards/past-ceremonies.html?_gl=1*1qn25im*_ga*MTA5MTEwOTI4Ni4xNjk4NTA5NTQz*_ga_ZJB8WQKN4E*MTY5ODUwOTU0Mi4xLjAuMTY5ODUwOTU0Mi42MC4wLjA.
mol
I see positions have been added to CFD / Spreadbet accounts today. I wonder if that will have any impact on the price. Unlike OPTI, it is possible to buy via leverage.
Thanks. Interesting that PBX are putting out info under Opti website. But don't mind if it saves money.
Bit of info
https://optibiotix.com/probiotix-health-highlights-lpldl-and-new-products-to-support-cardiometabolic-health-at-supplyside-west/
mol
Bit of coverage today
https://www.nutritionaloutlook.com/view/probiotix-health-adds-cholbiomevh-formula-to-cardiovascular-probiotics-line
mol
Seems like timing and terminology are key! Let's hope the following statement becomes booked revenue within H2.
"During the first half of the financial year the Group received confirmed orders totalling £1.5m which is 16% greater than turnover for the period to 31 December 2022 of £1.31m. Of the orders received, £552k (2021: £302k) had been completed and invoiced as at 30 June 2023. The increase in sales for the first half of the year reflects strong development in new customer acquisition as well as growth from existing customers. Gross profit for the period amounted to £264k (2022: £154k)."
And as you say reliance is spread over more large partners.
Disappointing in my opinion
And seed is our largest customer 9 months to Dec 22 £921k whilst 6 months to June 23 £342,530 - hopefully an improvement to come in 2nd months from them although we need to gain several more seeds to not only reduce reliance on them but to grow the business in any meaningful way in the coming months
I’ll review again at year end by which time we will hopefully be back on aim
Bw all
mol
Bit early to judge under new CEO. One ref to Aquis/AIM.
We will continue to work with Aquis and explore opportunities on other markets, including AIM, to increase liquidity in the Company's share price.
Has anyone thought of asking SOH for progress to AIM?
One week that suggested deadline.
Mind as we know this from 2020
https://lpldl.com/wp-content/uploads/2021/01/CholBiomeVH-A4-Leaflet-2020.pdf
albeit at least BHF reference is from May 2023 and Steen commenting as CEO is current in today's blog on opti site
mol
Https://optibiotix.com/probiotix-health-expands-heart-health-range-with-cholbiomevh/
mol
Taking over from T O'Hara seemingly
https://uk.linkedin.com/in/tom-o-hara-6a8686184
mol
Now headquarters apparently - didn't bother to find out how to put a slash across the leading o
https://dk.linkedin.com/company/probiotix-health?trk=public_post_main-feed-card_reshare-text
jees - lol
but really it's not funny
mol
And this
https://www.youtube.com/watch?v=KTWaaliOMkA
mol
And this under pbx banner
https://www.youtube.com/watch?v=xFcR1wtWJ8g
again 3 views - must be checking uploaded ok methinks
mol
Now released under Probiotix banner - 24 August 23
https://www.youtube.com/watch?v=21KkCHiHVI4
but same interview from a while ago
with only 3 views so far
mol
Or who in their right mind would contemplate selling these shares? And yet they do, selling at a paltry 6p rather than waiting.
I think SOH said the cost of transferring to AIM comes down after 18 months on AQSE. Which i think would be end of Sep. SOH has mentioned moving to AQSE, possibly then, but his comments are often vague on timescale. Again, I think he is aware of shareholders displeasure and mentions that Opti is the biggest shareholder. However, whilst he will have a say in any transfer of exchanges, presumably Steen will have too?
Agree, poor decision.
In the meantime Gwynth Paltrow is advertising Seed on Instagram...
Agreed Malco. Total waste of time. Didn't I read somewhere that there was a plan to do so?
when is soh going to admit he made a gigantic **** up placing this on aquis and move to aim.
with a current spread of 80% who in their right mind would even contemplate buying any shares?
Https://alumniglobal.com/job/head-of-supply-chain-pro-biotix-health
hardly surprising advertised in Denmark considering CEO and our recent technical product manager
another deerland employee perhaps to be appointed .......
anyway we were notified of increased employment numbers during 2023 - which per se I'm not opposed to - in fact welcome in order to grow the business - just hope it is the best people being appointed
and of course we haven't been notified of anything further on our new subsidiary, which i discovered several months ago now involving our new CEO, and its seemingly business purpose having not a lot to with lpldl nor anything remotely associated with probiotics
mol
Recent review 15 August 2023
https://www.healthcanal.com/health/digestion/seed-probiotics-review
not sure re their outreach but a positive review
still waiting Steen on at least another one seed in our portfolio of customers....
mind i expect many more than one - the undernoted doesn't come close
https://probiotixhealth-ir.com/news/archive/2023/010823
mol
Thanks mol, now go and have a well deserved lie down. =~)
Update re their, albeit small, in vitro trial
Extract
SH-DS01 capsules containing a 24-strain probiotic mixture encased in an Indian pomegranate (Punica granatum) outer envelope were obtained from Seed Health (Los Angeles, CA, USA). SH-DS01 contains the following strains:
Lactiplantibacillus plantarum SD-LPLDL-UK
amongst others - i've deleted others because of space constraints posting here
Our study has certain limitations and leaves a number of open questions. First, it uses an in vitro system as a model to approximate the human gut. This artificial system can introduce confounders into the model that make biological interpretations difficult. However, we contend that in vitro models using complex fecally derived communities can provide useful information regarding the short-term transit and activity of a synbiotic in the gastrointestinal tract, noting, however, that the use of a fecal community from a single individual does not capture interindividual variations in microbiome composition that may play a role in stress recovery. Second, our incubation times reflect roughly a 2-day exposure time and do not allow conclusions to be drawn on the long-term impact of synbiotics on recovery after stressors. Finally, transfer between reactors induces a bottleneck event that may modify community succession in a manner that would not occur in a true gut ecosystem. Nevertheless, the results shown here indicate the beneficial effects of a specific synbiotic product on the functional recovery of the gut microbiome in vitro following stress.
Overall, these experiments demonstrate the acute impact of alcohol and broad-spectrum antibiotics on the fecal microbiome in vitro and the potential for a microbial consortium to mitigate environmentally induced stress on the structure and function of the human gut microbiome in vivo. We contend that our results demonstrating the recovery of key aspects of healthy gut microbial function, specifically SCFA production, are relevant to predicting the potential effects of a synbiotic in humans. A well-designed clinical trial with deeper sequencing, additional measurements of microbial function, and a larger sample size will help to test the broader applicability of these findings and the role of synbiotics in the recovery of the human gut microbiome following exposure to stressors.
https://journals.asm.org/doi/epub/10.1128/aem.01880-22
mol